Year: 2021
Type: review
Abstract: Certain chronic comorbidities, including diabetes, are highly prevalent in people with coronavirus disease 2019 (COVID-19) and are associated with an increased risk of severe COVID-19 and mortality. Mild glucose elevations are also common in COVID-19 patients and associated with worse outcomes even in people without diabetes. Several studies have recently reported new-onset diabetes associated with COVID-19. The phenomenon of new-onset diabetes following admission to the hospital has been observed previously with other viral infections and acute illnesses. The precise mechanisms for new-onset diabetes in people with COVID-19 are not known, but it is likely that a number of complex interrelated processes are involved, including previously undiagnosed diabetes, stress hyperglycemia, steroid-induced hyperglycemia, and direct or indirect effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the β-cell. There is an urgent need for research to help guide management pathways for these patients. In view of increased mortality in people with new-onset diabetes, hospital protocols should include efforts to recognize and manage acute hyperglycemia, including diabetic ketoacidosis, in people admitted to the hospital. Whether new-onset diabetes is likely to remain permanent is not known, as the long-term follow-up of these patients is limited. Prospective studies of metabolism in the setting of postacute COVID-19 will be required to understand the etiology, prognosis, and treatment opportunities.
Source: Diabetes Care
DOI: 10.2337/dc21-1318
Institutions: Leicester General Hospital, University Hospitals of Leicester NHS Trust, University of Pisa, KU Leuven, University of Washington, VA Puget Sound Health Care System, American Diabetes Association, Harvard University, University of North Carolina at Chapel Hill, University of North Carolina Health Care
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Veterans Affairs, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Intarcia Therapeutics, Insulet Corporation, Dexcom, Moderna, National Institute for Health and Care Research, Department of Health and Social Care, KU Leuven, Novo Nordisk, Menarini Group, National Institutes of Health, NIHR Leicester Biomedical Research Centre, BERLIN-CHEMIE, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences
OpenAlex ID: W3203443071
